Posting Date: February 25, 2021

Closing Date: March 7, 2021 11:30 a.m. ET

Reference Number: 21-017982

To: NCI Bid Board

From: Tanya Proctor
NCI CCR P-ARC
Tanya.proctor@nih.gov

Subject: NCI Bid Board Posting – Service Agreement

At the National Cancer Institute (NCI), The Laboratory of Pathology (LP) is an integral component of the research and clinical community. Our goal is to be a globally recognized center of excellence in disease research, clinical diagnostics, and pathology education. The mission of the Laboratory of Pathology is to achieve the highest level of quality in research, diagnostics, and education. We support the research mission of the NCI by investigating the biology and genetics of cancer and other diseases, developing and applying leading edge technology to diagnostic pathology, providing collaborative support for clinical research protocols In this endeavor, we value scientific originality, integrity, and productivity while maintaining the highest level of ethical principles..

The National Cancer Institute plans to purchase Service Agreements for (SN: FNAS30P20021250) NanoFCM Flow NanoAnalyzer S30 from NanoFCM. This is not a request for competitive quotation. However, if any interested party believes it can meet the attached requirements, it may submit a statement of capabilities. The capability statement must be in writing and must contain information and material in sufficient detail to allow NCI to determine is the party can fully meet this requirement. The capability statement must be received in the contracting office by 11:30 AM on March 7, 2021 ET. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.

Sole Source Justification:

No suitable alternative vendors were found which could provide this required service, nor does the Translational Nanobiology Section anticipate any suitable alternative based on the custom nature of this instrument. From Dr Jennifer C. Jones and Dr Joshua Welsh's extensive experience and knowledge of the nano particle analysis marketplace through collaborators in the global research community and the latest published research in the field, no alternative vendor is known or anticipated which could provide the required service. Dr Jones and Dr Welsh consulted users of similar instruments both within NCI and outside the federal government to ensure the maintenance cost was fair and comparable

Attached Documents:
SF18
Statement of Work
FAR Clause 52.213-4 Simplified Acquisitions Terms and Conditions (JAN 2014) is applicable and available in full text upon request